As of this writing, we have 3 choices for a man with mCRPC and a BRCA2 mutation who has never had a prior ARSI and is now progressing on ADT with or without docetaxel in the mHSPC setting or ADT in the nmCRPc setting. Abiraterone plus olaparib has the longest follow up and a clearly significant over...

For me, this is based mostly on the coupling of the ARSI partner. I am selecting a PARPi combination that uses an ARSI not previously used. For instance, if an AR antagonist was selected then I will be prioritizing a combination with abiraterone. For patients previously treated with abiraterone, I w...

As we have the recent approval of 3 separate combinations, and assuming accessibility is not an issue, I review the patient’s co-morbidities, concomitant medications, issues of monitoring, and sometimes pill burden. Importantly, shared decision-making is a key component.